Diagnosing and Managing Polypoidal Choroidal Vasculopathy - Scorecard - MDSpire
Advertisement
Diagnosing and Managing Polypoidal Choroidal Vasculopathy
Polypoidal choroidal vasculopathy (PCV) is a distinct choroidal vascular disorder often considered a variant of age-related macular degeneration (AMD), although features such as drusen, pigmentary changes, and geographic atrophy are uncommon.
Clinical Scorecard: Diagnosing and Managing Polypoidal Choroidal Vasculopathy
At a Glance
Category
Detail
Condition
Key Mechanisms
Involves choroidal vascular lesions, often considered a variant of age-related macular degeneration (AMD). Genetic and demographic factors play a significant role.
Target Population
Care Setting
Key Highlights
PCV is associated with recurrent subretinal hemorrhages and pigment epithelial detachments. Genetic studies indicate involvement of inflammatory pathways and lipid metabolism.
Diagnosis is confirmed via indocyanine green angiography (ICGA) and multimodal imaging, including OCT.
Treatment options include photodynamic therapy (PDT) and intravitreal anti-VEGF therapy, with consideration of patient demographics.
Guideline-Based Recommendations
Diagnosis
PCV diagnosis requires focal hyperfluorescence and at least one additional characteristic finding, including specific imaging results.
Management
Treatment options include PDT, intravitreal anti-VEGF therapy, and laser photocoagulation, with emphasis on multimodal imaging.
Monitoring & Follow-up
Regular follow-up with multimodal imaging, including OCT, to assess treatment response and disease progression.
Risks
Poor response to anti-VEGF therapy may indicate PCV rather than other chorioretinal disorders.
Patient & Prescribing Data
Combination therapies may enhance treatment efficacy in managing PCV, especially in patients with suboptimal responses to conventional treatments.
Clinical Best Practices
Utilize multimodal imaging for accurate diagnosis and monitoring, including OCT.
Consider genetic and demographic factors in treatment planning.
Supplying ocular nutritional supplements (ONS) is a way to deepen patient trust and improve their visual outcomes, with the byproduct a new revenue stream. This is the theme of this issue of Optometric Management.
AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it.